Vitrolife AB (publ) Logo

Vitrolife AB (publ)

VITR.ST

(3.2)
Stock Price

220,40 SEK

-147.82% ROA

-26.91% ROE

-8.45x PER

Market Cap.

32.088.480.384,00 SEK

15.42% DER

0.42% Yield

-107.5% NPM

Vitrolife AB (publ) Stock Analysis

Vitrolife AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vitrolife AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a minimal amount of debt (12%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

5 ROE

The stock's ROE falls within an average range (2.34%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

6 PBV

The stock's PBV ratio (1.34x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

7 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

8 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

9 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (1.522) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Vitrolife AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vitrolife AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Vitrolife AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vitrolife AB (publ) Revenue
Year Revenue Growth
2002 103.283.000
2003 96.256.000 -7.3%
2004 103.855.000 7.32%
2005 120.120.000 13.54%
2006 171.264.000 29.86%
2007 188.939.000 9.35%
2008 225.141.000 16.08%
2009 274.626.000 18.02%
2010 297.565.000 7.71%
2011 356.115.000 16.44%
2012 362.020.000 1.63%
2013 452.738.000 20.04%
2014 510.512.000 11.32%
2015 722.370.000 29.33%
2016 856.106.000 15.62%
2017 1.046.217.000 18.17%
2018 1.151.348.000 9.13%
2019 1.480.132.000 22.21%
2020 1.245.572.000 -18.83%
2021 1.680.804.000 25.89%
2022 3.234.000.000 48.03%
2023 3.392.000.000 4.66%
2023 3.512.000.000 3.42%
2024 3.764.000.000 6.7%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vitrolife AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2002 30.642.000
2003 13.964.000 -119.44%
2004 12.228.000 -14.2%
2005 15.819.000 22.7%
2006 24.183.000 34.59%
2007 26.889.000 10.06%
2008 30.669.000 12.33%
2009 38.574.000 20.49%
2010 43.144.000 10.59%
2011 47.176.000 8.55%
2012 41.204.000 -14.49%
2013 58.874.000 30.01%
2014 41.925.000 -40.43%
2015 55.737.000 24.78%
2016 61.590.000 9.5%
2017 69.116.000 10.89%
2018 88.457.000 21.86%
2019 99.515.000 11.11%
2020 91.759.000 -8.45%
2021 114.450.000 19.83%
2022 143.000.000 19.97%
2023 124.000.000 -15.32%
2023 122.000.000 -1.64%
2024 104.000.000 -17.31%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vitrolife AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 33.658.000
2003 25.110.000 -34.04%
2004 20.590.000 -21.95%
2005 20.525.000 -0.32%
2006 24.339.000 15.67%
2007 28.775.000 15.42%
2008 35.449.000 18.83%
2009 38.831.000 8.71%
2010 82.224.000 52.77%
2011 50.576.000 -62.58%
2012 45.170.000 -11.97%
2013 55.891.000 19.18%
2014 59.960.000 6.79%
2015 80.467.000 25.48%
2016 94.146.000 14.53%
2017 99.334.000 5.22%
2018 99.270.000 -0.06%
2019 119.382.000 16.85%
2020 114.424.000 -4.33%
2021 259.456.000 55.9%
2022 400.000.000 35.14%
2023 384.000.000 -4.17%
2023 433.000.000 11.32%
2024 472.000.000 8.26%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vitrolife AB (publ) EBITDA
Year EBITDA Growth
2002 124.694.000
2003 44.271.000 -181.66%
2004 13.042.000 -239.45%
2005 22.165.000 41.16%
2006 16.594.000 -33.57%
2007 20.678.000 19.75%
2008 27.125.000 23.77%
2009 30.408.000 10.8%
2010 50.834.000 40.18%
2011 41.411.000 -22.75%
2012 77.401.000 46.5%
2013 123.761.000 37.46%
2014 168.418.000 26.52%
2015 262.902.000 35.94%
2016 304.198.000 13.58%
2017 407.581.000 25.37%
2018 482.589.000 15.54%
2019 594.978.000 18.89%
2020 443.852.000 -34.05%
2021 577.042.000 23.08%
2022 995.000.000 42.01%
2023 720.000.000 -38.19%
2023 1.158.000.000 37.82%
2024 1.388.000.000 16.57%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vitrolife AB (publ) Gross Profit
Year Gross Profit Growth
2002 49.362.000
2003 61.639.000 19.92%
2004 74.374.000 17.12%
2005 82.927.000 10.31%
2006 116.520.000 28.83%
2007 129.665.000 10.14%
2008 156.250.000 17.01%
2009 192.885.000 18.99%
2010 206.155.000 6.44%
2011 238.273.000 13.48%
2012 238.300.000 0.01%
2013 300.555.000 20.71%
2014 349.118.000 13.91%
2015 484.820.000 27.99%
2016 561.301.000 13.63%
2017 681.709.000 17.66%
2018 761.124.000 10.43%
2019 938.652.000 18.91%
2020 767.667.000 -22.27%
2021 1.046.090.000 26.62%
2022 1.780.000.000 41.23%
2023 1.892.000.000 5.92%
2023 1.738.000.000 -8.86%
2024 1.996.000.000 12.93%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vitrolife AB (publ) Net Profit
Year Net Profit Growth
2002 116.503.000
2003 44.684.000 -160.73%
2004 11.936.000 -274.36%
2005 14.859.000 19.67%
2006 15.199.000 2.24%
2007 36.057.000 57.85%
2008 29.995.000 -20.21%
2009 34.114.000 12.07%
2010 29.182.000 -16.9%
2011 30.360.000 3.88%
2012 333.772.000 90.9%
2013 56.274.000 -493.12%
2014 109.109.000 48.42%
2015 182.845.000 40.33%
2016 190.368.000 3.95%
2017 263.640.000 27.79%
2018 309.697.000 14.87%
2019 382.785.000 19.09%
2020 286.845.000 -33.45%
2021 341.000.000 15.88%
2022 394.000.000 13.45%
2023 488.000.000 19.26%
2023 -3.851.000.000 112.67%
2024 572.000.000 773.25%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vitrolife AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 1
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 3 100%
2013 1 0%
2014 1 100%
2015 2 0%
2016 2 0%
2017 2 50%
2018 3 0%
2019 4 33.33%
2020 3 -50%
2021 3 0%
2022 3 0%
2023 4 33.33%
2023 -28 110.71%
2024 4 800%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vitrolife AB (publ) Free Cashflow
Year Free Cashflow Growth
2002 -19.561.000
2003 30.731.000 163.65%
2004 -643.000 4879.32%
2005 7.107.000 109.05%
2006 16.066.000 55.76%
2007 15.067.000 -6.63%
2008 2.444.000 -516.49%
2009 16.606.000 85.28%
2010 48.399.000 65.69%
2011 1.649.000 -2835.05%
2012 42.575.000 96.13%
2013 97.636.000 56.39%
2014 136.746.000 28.6%
2015 170.897.000 19.98%
2016 167.510.000 -2.02%
2017 301.716.000 44.48%
2018 169.328.000 -78.18%
2019 326.233.000 48.1%
2020 336.362.000 3.01%
2021 321.858.000 -4.51%
2022 549.000.000 41.37%
2023 637.000.000 13.81%
2023 214.000.000 -197.66%
2024 197.000.000 -8.63%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vitrolife AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2002 34.774.000
2003 31.205.000 -11.44%
2004 14.005.000 -122.81%
2005 14.121.000 0.82%
2006 23.784.000 40.63%
2007 21.285.000 -11.74%
2008 42.793.000 50.26%
2009 41.478.000 -3.17%
2010 48.399.000 14.3%
2011 39.460.000 -22.65%
2012 59.930.000 34.16%
2013 106.127.000 43.53%
2014 145.666.000 27.14%
2015 193.526.000 24.73%
2016 181.262.000 -6.77%
2017 312.189.000 41.94%
2018 349.435.000 10.66%
2019 413.333.000 15.46%
2020 356.448.000 -15.96%
2021 384.306.000 7.25%
2022 636.000.000 39.57%
2023 757.000.000 15.98%
2023 214.000.000 -253.74%
2024 236.000.000 9.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vitrolife AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2002 54.335.000
2003 474.000 -11363.08%
2004 14.648.000 96.76%
2005 7.014.000 -108.84%
2006 7.718.000 9.12%
2007 6.218.000 -24.12%
2008 40.349.000 84.59%
2009 24.872.000 -62.23%
2010 0 0%
2011 37.811.000 100%
2012 17.355.000 -117.87%
2013 8.491.000 -104.39%
2014 8.920.000 4.81%
2015 22.629.000 60.58%
2016 13.752.000 -64.55%
2017 10.473.000 -31.31%
2018 180.107.000 94.19%
2019 87.100.000 -106.78%
2020 20.086.000 -333.64%
2021 62.448.000 67.84%
2022 87.000.000 28.22%
2023 120.000.000 27.5%
2023 0 0%
2024 39.000.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vitrolife AB (publ) Equity
Year Equity Growth
2002 111.401.000
2003 143.435.000 22.33%
2004 150.574.000 4.74%
2005 176.450.000 14.66%
2006 220.639.000 20.03%
2007 253.384.000 12.92%
2008 292.388.000 13.34%
2009 312.069.000 6.31%
2010 326.333.000 4.37%
2011 343.903.000 5.11%
2012 278.982.000 -23.27%
2013 322.600.000 13.52%
2014 702.571.000 54.08%
2015 844.972.000 16.85%
2016 1.020.384.000 17.19%
2017 1.228.649.000 16.95%
2018 1.496.212.000 17.88%
2019 1.797.628.000 16.77%
2020 2.017.014.000 10.88%
2021 15.340.870.000 86.85%
2022 16.740.000.000 8.36%
2023 12.723.000.000 -31.57%
2023 17.431.000.000 27.01%
2024 13.097.000.000 -33.09%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vitrolife AB (publ) Assets
Year Assets Growth
2002 188.515.000
2003 183.995.000 -2.46%
2004 185.538.000 0.83%
2005 211.370.000 12.22%
2006 271.034.000 22.01%
2007 299.460.000 9.49%
2008 342.662.000 12.61%
2009 359.315.000 4.63%
2010 429.388.000 16.32%
2011 466.780.000 8.01%
2012 462.198.000 -0.99%
2013 487.808.000 5.25%
2014 972.482.000 49.84%
2015 1.059.243.000 8.19%
2016 1.250.491.000 15.29%
2017 1.422.424.000 12.09%
2018 1.697.467.000 16.2%
2019 2.138.687.000 20.63%
2020 2.305.089.000 7.22%
2021 19.428.796.000 88.14%
2022 20.551.000.000 5.46%
2023 16.391.000.000 -25.38%
2023 21.180.000.000 22.61%
2024 16.852.000.000 -25.68%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vitrolife AB (publ) Liabilities
Year Liabilities Growth
2002 77.114.000
2003 40.560.000 -90.12%
2004 34.964.000 -16.01%
2005 34.920.000 -0.13%
2006 50.395.000 30.71%
2007 46.076.000 -9.37%
2008 50.274.000 8.35%
2009 47.246.000 -6.41%
2010 103.055.000 54.15%
2011 122.877.000 16.13%
2012 183.216.000 32.93%
2013 165.208.000 -10.9%
2014 269.911.000 38.79%
2015 214.271.000 -25.97%
2016 230.107.000 6.88%
2017 193.775.000 -18.75%
2018 201.255.000 3.72%
2019 341.059.000 40.99%
2020 288.075.000 -18.39%
2021 4.087.926.000 92.95%
2022 3.811.000.000 -7.27%
2023 3.668.000.000 -3.9%
2023 3.749.000.000 2.16%
2024 3.755.000.000 0.16%

Vitrolife AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
26.1
Net Income per Share
-28.06
Price to Earning Ratio
-8.45x
Price To Sales Ratio
9.08x
POCF Ratio
39.18
PFCF Ratio
47.89
Price to Book Ratio
2.45
EV to Sales
9.43
EV Over EBITDA
30.41
EV to Operating CashFlow
40.7
EV to FreeCashFlow
49.75
Earnings Yield
-0.12
FreeCashFlow Yield
0.02
Market Cap
32,09 Bil.
Enterprise Value
33,33 Bil.
Graham Number
247.09
Graham NetNet
-16.19

Income Statement Metrics

Net Income per Share
-28.06
Income Quality
-0.22
ROE
-0.27
Return On Assets
-0.23
Return On Capital Employed
0.05
Net Income per EBT
1.04
EBT Per Ebit
-4.72
Ebit per Revenue
0.22
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.52
Operating Profit Margin
0.22
Pretax Profit Margin
-1.03
Net Profit Margin
-1.07

Dividends

Dividend Yield
0
Dividend Yield %
0.42
Payout Ratio
-0.04
Dividend Per Share
1

Operating Metrics

Operating Cashflow per Share
6.05
Free CashFlow per Share
4.95
Capex to Operating CashFlow
0.18
Capex to Revenue
0.04
Capex to Depreciation
0.34
Return on Invested Capital
0.05
Return on Tangible Assets
-1.48
Days Sales Outstanding
71.99
Days Payables Outstanding
36.03
Days of Inventory on Hand
80.46
Receivables Turnover
5.07
Payables Turnover
10.13
Inventory Turnover
4.54
Capex per Share
1.1

Balance Sheet

Cash per Share
6,30
Book Value per Share
96,73
Tangible Book Value per Share
-8.75
Shareholders Equity per Share
96.72
Interest Debt per Share
15.58
Debt to Equity
0.15
Debt to Assets
0.12
Net Debt to EBITDA
1.13
Current Ratio
2.99
Tangible Asset Value
-1,19 Bil.
Net Current Asset Value
-1,76 Bil.
Invested Capital
15990000000
Working Capital
1,33 Bil.
Intangibles to Total Assets
0.85
Average Receivables
0,67 Bil.
Average Payables
0,17 Bil.
Average Inventory
383000000
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vitrolife AB (publ) Dividends
Year Dividends Growth
2009 0
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 100%
2015 2 0%
2016 2 50%
2017 3 0%
2018 4 33.33%
2019 1 0%
2020 1 100%
2021 1 0%
2022 1 0%
2023 1 0%
2024 1 100%

Vitrolife AB (publ) Profile

About Vitrolife AB (publ)

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

CEO
Ms. Bronwyn Brophy O´Connor
Employee
1.115
Address
Gustaf Werners gata 2
Gothenburg, 421 32

Vitrolife AB (publ) Executives & BODs

Vitrolife AB (publ) Executives & BODs
# Name Age
1 Mr. Claus Bisgaard
Senior Vice President of Technologies
70
2 Guillermo Ferrando
Vice President Strategy & Corporate development
70
3 Mr. Rickard Ericsson
Senior Vice President of Consumables
70
4 Ricardo Capella
Senior Vice President Genetic Services
70
5 Frank Pettersson
Acting Senior Vice President of HR & Sustainability
70
6 Olivia Natens
Senior Vice President of Sales & Marketing
70
7 Mr. Patrik Tolf
Chief Financial Officer
70
8 Ms. Bronwyn Brophy O´Connor
Chief Executive Officer & President
70

Vitrolife AB (publ) Competitors